Original Research

  1. Lin AG, Xiang B, Merlino DJ, Baybutt TR, Sahu J, Fridman A, et al. Non-thermal plasma induces immunogenic cell death in vivo in murine CT26 colorectal tumors. Oncoimmunology. 2018 Jul 26;7(9):e1484978. PMID 30228954, PMCID PMC6140551

  2. Magee MS, Abraham TS, Baybutt TR, Flickinger JC, Jr., Ridge NA, Marszalowicz GP, Prajapati P, Hersperger AR, Waldman SA, Snook AE. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res. 2018;6:509-16. PMID 29615399, PMCID PMC59322

  3. Xiang B, Baybutt TR, Berman-Booty L, Magee MS, Waldman SA, Alexeev VY, Snook AE. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8(+) T Cells. J Immunol. 2017;198:3507-14. PMID 28341670, PMCID PMC5435941

  4. Thangavel C, Boopathi E, Liu Y, Haber A, Ertel A, Bhardwaj A, Addya S, Williams N, Ciment SJ, Cotzia P, Dean JL, Snook AE, McNair C, Price M, Hernandez JR, Zhao SG, Birbe R, McCarthy JB, Turley EA, Pienta KJ, Feng FY, Dicker AP, Knudsen KE, Den RB. RB Loss Promotes Prostate Cancer Metastasis. Cancer Res. 2017;77:982-95. PMID 27923835, PMCID PMC5700768

  5. Perepelyuk M, Shoyele O, Birbe R, Thangavel C, Liu Y, Den RB, Snook AE, Lu B, Shoyele SA. siRNA-Encapsulated Hybrid Nanoparticles Target Mutant K-ras and Inhibit Metastatic Tumor Burden in a Mouse Model of Lung Cancer. Mol Ther Nucleic Acids. 2017;6:259-68. PMID 28325292, PMCID PMC5363504

  6. Li P, Wuthrick E, Rappaport JA, Kraft C, Lin JE, Marszalowicz G, Snook AE, Zhan T, Hyslop TM, Waldman SA. GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome. Cancer Res. 2017;77:5095-106. PMID 28916678, PMCID PMC5678756

  7. Li P, Lin JE, Snook AE, Waldman SA. ST-Producing E. coli Oppose Carcinogen-Induced Colorectal Tumorigenesis in Mice. Toxins (Basel). 2017;9. PMID 28895923, PMCID PMC5618212

  8. Kraft CL, Rappaport JA, Snook AE, Pattison AM, Lynch JP, Waldman SA. GUCY2C maintains intestinal LGR5(+) stem cells by opposing ER stress. Oncotarget. 2017;8:102923-33. PMID 29262534, PMCID PMC5732700

  9. Snook AE, Baybutt TR, Hyslop T, Waldman SA. Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope. Hum Gene Ther Methods. 2016;27:238-50. PMID 27903079, PMCID PMC5175423

  10. Perepelyuk M, Thangavel C, Liu Y, Den RB, Lu B, Snook AE, Shoyele SA. Biodistribution and Pharmacokinetics Study of siRNA-loaded Anti-NTSR1-mAb-functionalized Novel Hybrid Nanoparticles in a Metastatic Orthotopic Murine Lung Cancer Model. Mol Ther Nucleic Acids. 2016;5:e282. PMID 26812654, PMCID PMC5012553

  11. Pattison AM, Blomain ES, Merlino DJ, Wang F, Crissey MA, Kraft CL, Rappaport JA, Snook AE, Lynch JP, Waldman SA. Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins. Infect Immun. 2016;84:3083-91. PMID 27481254, PMCID PMC5038068

  12. Magee MS, Kraft CL, Abraham TS, Baybutt TR, Marszalowicz GP, Li P, Waldman SA, Snook AE. GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. Oncoimmunology. 2016;5:e1227897. PMID 27853651, PMCID PMC5087292

  13. Lin JE, Colon-Gonzalez F, Blomain E, Kim GW, Aing A, Stoecker B, Rock J, Snook AE, Zhan T, Hyslop TM, Tomczak M, Blumberg RS, Waldman SA. Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis. Cancer Res. 2016;76:339-46. PMID 26773096, PMCID PMC4717834

  14. Snook AE, Baybutt T, Mastrangelo M, Lewis N, Goldstein S, Kraft W, Oppong Y, Hyslop T, Myers R, Alexeev V, Eisenlohr L, Sato T, Waldman S. A Phase I study of AD5-GUCY2C-PADRE in stage I and II colon cancer patients. Journal for ImmunoTherapy of Cancer. 2015;3:P450. PMCID PMC4652457

  15. Krishnan V, Xu X, Kelly D, Snook AE, Waldman SA, Mason RW, Jia X, Rajasekaran AK. CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-Cell Acute Lymphoblastic Leukemia. Mol Pharm. 2015;12:2101-11. PMID 25898125, PMCID PMC4540184

  16. Goodwin JF, Kothari V, Drake JM, Zhao S, Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Jones JK, Aytes A, Magee MS, Snook AE, Zhu Z, Den RB, Birbe RC, Gomella LG, Graham NA, Vashisht AA, Wohlschlegel JA, Graeber TG, Karnes RJ, Takhar M, Davicioni E, Tomlins SA, Abate-Shen C, Sharifi N, Witte ON, Feng FY, Knudsen KE. DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. Cancer Cell. 2015;28:97-113. PMID 26175416, PMCID PMC4531387

  17. Witek ME, Snook AE, Lin JE, Blomain ES, Xiang B, Magee MS, Waldman SA. A novel CDX2 isoform regulates alternative splicing. PloS one. 2014;9:e104293. PMID 25101906, PMCID PMC4125279

  18. Witek M, Blomain ES, Magee MS, Xiang B, Waldman SA, Snook AE. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C. Int J Radiat Oncol Biol Phys. 2014;88:1188-95. PMID 24661671, PMCID PMC3967134

  19. Wilson C, Lin JE, Li P, Snook AE, Gong J, Sato T, Liu C, Girondo MA, Rui H, Hyslop T, Waldman SA. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2014;23:2328-37. PMID 25304930, PMCID PMC4221461

  20. Snook AE, Magee MS, Schulz S, Waldman SA. Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy. Eur J Immunol. 2014;44:1956-66. PMID 24771148, PMCID PMC4107120

  21. Marszalowicz GP, Snook AE, Magee MS, Merlino D, Berman-Booty LD, Waldman SA. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer. Oncotarget. 2014;5:9460-71. PMID 25294806, PMCID PMC4253446

  22. Hersperger AR, Siciliano NA, DeHaven BC, Snook AE, Eisenlohr LC. Epithelial immunization induces polyfunctional CD8+ T cells and optimal mousepox protection. J Virol. 2014;88:9472-5. PMID 24899206, PMCID PMC4136261

  23. Hayes CS, Shicora AC, Keough MP, Snook AE, Burns MR, Gilmour SK. Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment. Cancer Immunol Res. 2014;2:274-85. PMID 24778323, PMCID PMC4101915

  24. Gibbons AV, Lin JE, Kim GW, Marszalowicz GP, Li P, Stoecker BA, Blomain ES, Rattan S, Snook AE, Schulz S, Waldman SA. Intestinal GUCY2C prevents TGF-beta secretion coordinating desmoplasia and hyperproliferation in colorectal cancer. Cancer Res. 2013;73:6654-66. PMID 24085786, PMCID PMC3838632

  25. Snook AE, Magee MS, Marszalowicz GP, Schulz S, Waldman SA. Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C. Cancer Immunol Immunother. 2012;61:713-23. PMID 22057677

  26. Lin JE, Snook AE, Li P, Stoecker BA, Kim GW, Magee MS, Garcia AV, Valentino MA, Hyslop T, Schulz S, Waldman SA. GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity. PloS one. 2012;7:e31686. PMID 22384056, PMCID PMC3284579

  27. Valentino MA, Lin JE, Snook AE, Li P, Kim GW, Marszalowicz G, Magee MS, Hyslop T, Schulz S, Waldman SA. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. J Clin Invest. 2011;121:3578-88. PMID 21865642, PMCID PMC3223926

  28. Comber JD, Robinson TM, Siciliano NA, Snook AE, Eisenlohr LC. Functional macroautophagy induction by influenza A virus without a contribution to major histocompatibility complex class II-restricted presentation. J Virol. 2011;85:6453-63. PMID 21525345, PMCID PMC3126538

  29. Lin JE, Li P, Snook AE, Schulz S, Dasgupta A, Hyslop TM, Gibbons AV, Marszlowicz G, Pitari GM, Waldman SA. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling. Gastroenterology. 2010;138:241-54. PMID 19737566, PMCID PMC2813361

  30. Snook AE, Li P, Stafford BJ, Faul EJ, Huang L, Birbe RC, Bombonati A, Schulz S, Schnell MJ, Eisenlohr LC, Waldman SA. Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res. 2009;69:3537-44. PMID 19351847, PMCID PMC2707278

  31. Gong L, Debruyne PR, Witek M, Nielsen K, Snook AE, Lin JE, Bombonati A, Palazzo J, Schulz S, Waldman SA. Bile acids initiate lineage-addicted gastroesophageal tumorigenesis by suppressing the EGF receptor-AKT axis. Clinical and translational science. 2009;2:286-93. PMID 20443907, PMCID PMC5407481

  32. Snook AE, Huang L, Schulz S, Eisenlohr LC, Waldman SA. Cytokine adjuvanation of therapeutic anti-tumor immunity targeted to cancer mucosa antigens. Clinical and translational science. 2008;1:263-4. PMID 19956776, PMCID PMC2718574

  33. Snook AE, Stafford BJ, Li P, Tan G, Huang L, Birbe R, Schulz S, Schnell MJ, Thakur M, Rothstein JL, Eisenlohr LC, Waldman SA. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst. 2008;100:950-61. PMID 18577748, PMCID PMC2749952

  34. Plesa G, Snook AE, Waldman SA, Eisenlohr LC. Derivation and fluidity of acutely induced dysfunctional CD8+ T cells. J Immunol. 2008;180:5300-8. PMID 18390711

 

Reviews and Commentaries

  1. Flickinger JC, Jr., Rodeck U, Snook AE. Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress. Vaccines (Basel). 2018;6. PMID 30044426, PMCID PMC6160973

  2. Bashir B, Snook AE. Immunotherapy regimens for metastatic colorectal carcinomas. Hum Vaccin Immunother. 2018;14:250-4. PMID 29083978, PMCID PMC5806658

  3. Baybutt TR, Aka AA, Snook AE. Immunotherapy in Colorectal Cancer: Where Are We Now? Current Colorectal Cancer Reports. 2017;13:353-61.

  4. Baybutt TR, Aka AA, Snook AE. The Heat-Stable Enterotoxin Receptor, Guanylyl Cyclase C, as a Pharmacological Target in Colorectal Cancer Immunotherapy: A Bench-to-Bedside Current Report. Toxins (Basel). 2017;9. PMID 28914772, PMCID PMC5618215

  5. Aka AA, Rappaport JA, Pattison AM, Sato T, Snook AE, Waldman SA. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. Expert review of clinical pharmacology. 2017;10:549-57. PMID 28162021, PMCID PMC5742255

  6. Abraham TS, Snook AE. The swinging pendulum of cancer immunotherapy personalization. Per Med. 2017;14:259-70. PMID 29767586

  7. Pattison AM, Abraham TS, Merlino DJ, Lin JE, Saw TA, Snook AE, Waldman SA. Targeting guanylate cyclase C in colorectal cancer: Where are we now? Drugs of the Future. 2016;41:477-84.

  8. Blomain ES, Merlino DJ, Pattison AM, Snook AE, Waldman SA. Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer. Mol Pharmacol. 2016;90:199-204. PMID 27251363, PMCID PMC4998665

  9. Abraham TS, Snook AE. A novel role for Cish in the inhibition of TCR signaling. Translational Cancer Research. 2016;5:S142-S5.

  10. Witek M, Siglin J, Malatesta T, Snook AE, Gressen E, Rudoler S, Bar-Ad V, Fisher S. Is financial literacy necessary for radiation oncology residents? Int J Radiat Oncol Biol Phys. 2014;90:986-7. PMID 25539362

  11. Snook AE. Could targeting T-helper cells aid the development of effective cancer vaccines? Immunotherapy. 2014;6:959-61. PMID 25341117

  12. Magee MS, Snook AE. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer. Discovery medicine. 2014;18:265-71. PMID 25425467

  13. Xiang B, Snook AE, Magee MS, Waldman SA. Colorectal cancer immunotherapy. Discovery medicine. 2013;15:301-8. PMID 23725603, PMCID PMC4042089

  14. Snook AE, Waldman SA. Advances in cancer immunotherapy. Discovery medicine. 2013;15:120-5. PMID 23449114, PMCID PMC4066887

  15. Magee MS, Snook AE, Marszalowicz GP, Waldman SA. Immunotherapeutic strategies to target prognostic and predictive markers of cancer. Biomarkers in medicine. 2013;7:23-35. PMID 23387482, PMCID PMC3755011

  16. Blomain ES, Lin JE, Kraft CL, Trela UT, Rock JM, Aing AS, Snook AE, Waldman SA. Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis. Expert review of clinical pharmacology. 2013;6:557-64. PMID 23971873, PMCID PMC4048542

  17. Snook AE, Magee MS, Waldman SA. GUCY2C-targeted cancer immunotherapy: past, present and future. Immunol Res. 2011;51:161-9. PMID 22038530

  18. Lin JE, Valentino M, Marszalowicz G, Magee MS, Li P, Snook AE, Stoecker BA, Chang C, Waldman SA. Bacterial Heat-Stable Enterotoxins: Translation of Pathogenic Peptides into Novel Targeted Diagnostics and Therapeutics. Toxins. 2010;2:2028-54.

  19. Snook AE, Waldman SA. Cancer Mucosa Antigens a Novel Paradigm in Cancer Immunotherapeutics. Bioforum Eur. 2009;3:14-6. PMID 26855637, PMCID PMC4742354

  20. Chang C, Marszlowicz G, Waldman Z, Li P, Snook AE, Lin JE, Schulz S, Waldman SA. Guanylyl cyclase C as a biomarker for targeted imaging and therapy of metastatic colorectal cancer. Biomarkers in medicine. 2009;3:33-45. PMID 20477494

  21. Li P, Lin JE, Snook AE, Gibbons AV, Zuzga DS, Schulz S, Pitari GM, Waldman SA. Colorectal cancer is a paracrine deficiency syndrome amenable to oral hormone replacement therapy. Clinical and translational science. 2008;1:163-7. PMID 19727435, PMCID PMC2707021

  22. Snook AE, Stafford BJ, Eisenlohr LC, Rothstein JL, Waldman SA. Mucosally restricted antigens as novel immunological targets for antitumor therapy. Biomarkers in medicine. 2007;1:187-202. PMID 20477468

  23. Snook AE, Eisenlohr LC, Rothstein JL, Waldman SA. Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen. Clinical pharmacology and therapeutics. 2007;82:734-9. PMID 17898707

  24. Pitari GM, Li P, Lin JE, Zuzga D, Gibbons AV, Snook AE, Schulz S, Waldman SA. The paracrine hormone hypothesis of colorectal cancer. Clinical pharmacology and therapeutics. 2007;82:441-7. PMID 17687268

 

Book Chapters

  1. Abraham TS, Foreman AL, Snook AE. CD4⁺ T Cells: The Nexus of Tolerance, Autoimmunity, and Tumor Immunity. In: Boudewijn B, editor. Helper T Cells: Types, Functions and New Research. Hauppauge, NY: Nova Science Publishers, Inc.; 2018. p. 37-53.

  2. Snook AE, Blomain ES, Aing AS, Merlino D, Waldman SA. Guanylyl Cyclase Receptors. In: Bradshaw RA, Stahl PD, editors. Encyclopedia of Cell Biology. Waltham: Academic Press; 2016. p. 56-60.

  3. Magee MS, Snook AE, Waldman SA. Adoptive Cell Therapy: At the Forefront of Cancer Immunotherapy. In: Watanabe HS, editor. Horizons in Cancer Research. Hauppauge, NY: Nova Science Publishers, Inc.; 2013.

  4. Magee MS, Snook AE, Siciliano NA, Waldman SA. Barriers to, and Prospective Solutions for, Colorectal Cancer Immunotherapy. In: Villanueva CJ, editor. Immunogenicity. Hauppauge, NY: Nova Science Publishers, Inc.; 2011. p. 189-214.

 

Presentations

  1. Snook AE. September 2018. Translating CAR-T to Gastrointestinal Malignancies. Expert Forum on Gastrointestinal Malignancies in Dallas, Texas.

  2. Snook AE. June 2018. Progress and Opportunities in Cancer Immunotherapy. The 7th International Conference on Plasma Medicine (ICPM-7) in Philadelphia, Pennsylvania.

  3. Snook AE. April 2018. GUCY2C-Targeted CAR-T Cell Therapy for Gastrointestinal Cancers. Cancer & Immunotherapy Symposium 2018, hosted by ACEA Biosciences in Chicago, Illinois.

  4. Snook AE. December 2017. Development of GUCY2C-Targeted CAR-T Cell Therapy for Metastatic Colorectal Cancer. The American Society for Cell Biology (ASCB) / European Molecular Biology Organization (EMBO) 2017 Meeting in Philadelphia, Pennsylvania.

  5. Snook AE. November 2017. GUCY2C as an Immunotherapeutic Target in Gastrointestinal Malignancies. La Salle University Biology Club Seminar Series in Philadelphia, Pennsylvania.

  6. Snook AE. December 2008. Cancer Mucosa Antigens Are Novel Immunological Targets for Tumor Therapy. Presentat at Tumor Immunology: New Perspectives, hosted by the American Association for Cancer Research in Miami, Florida.

  7. Snook AE. May 2008. Cancer Mucosa Antigens as Novel Immunological Targets for Tumor Therapy. Presented at Advances in Cancer Vaccines, hosted by Cambridge Healthtech Institute in Cambridge Massachusetts.